Free Cash Flow Chart

Historical Free Cash Flow Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -170.67M
March 31, 2026 -175.90M
December 31, 2025 -172.59M
September 30, 2025 -144.04M
June 30, 2025 -124.30M
March 31, 2025 -107.38M
December 31, 2024 -97.05M
September 30, 2024 -95.11M
June 30, 2024 -83.61M
March 31, 2024 -79.79M
December 31, 2023 -73.89M
September 30, 2023 -82.36M
June 30, 2023 -82.75M
March 31, 2023 -86.36M
December 31, 2022 -84.55M
September 30, 2022 -85.95M
June 30, 2022 -88.12M
Date Value
March 31, 2022 -84.04M
December 31, 2021 -87.71M
September 30, 2021 -89.20M
June 30, 2021 -97.47M
March 31, 2021 -102.49M
December 31, 2020 -110.53M
September 30, 2020 -113.77M
June 30, 2020 -99.82M
March 31, 2020 -90.52M
December 31, 2019 -72.77M
September 30, 2019 -55.94M
June 30, 2019 -51.89M
March 31, 2019 -45.06M
December 31, 2018 -36.78M
September 30, 2018 -33.34M
June 30, 2018 -21.34M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Xencor, Inc. -208.28M
MeiraGTx Holdings Plc 10.06M
Insmed, Inc. -837.67M
Ironwood Pharmaceuticals, Inc. 185.55M
Viking Therapeutics, Inc. -418.44M